Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McKesson launches independent pharmacy transfer program

Executive Summary

Pharmaceutical wholesaler McKesson on July 7 launched its RxOwnership program, a service that provides independent pharmacy owners with business resources and confidential consulting services to transfer ownership to buyers looking to continue operating the pharmacy as an independent. McKesson said the service is not designed for independent owners to sell to chain operators. The wholesaler appointed independent owner Bob Graul to the newly created role of ownership consultant. He will be responsible for the overall strategy, coordination and implementation of the program. Some independent pharmacies have said their challenges have been worsened by expenses related to Medicare Part D. H.R. 6331, now awaiting presidential review, addresses one aspect of Part D, by requiring prompt payment to pharmacies of Part D claims

You may also be interested in...



Vaccine Hesitancy May Drive Distribution Priorities For Early COVID-19 Supply

ACIP defers vote on who should be inoculated first until it has data on a specific product, but vaccine acceptance among different groups could be weighed as factor in setting distribution priorities, committee members suggest.

China’s Cosmetic Animal-Testing Exemption ‘Not A Terribly Meaningful Solution’ – PCPC

The Personal Care Products Council’s Francine Lamoriello, EVP of global strategies, discusses shortcomings of a proposed animal-testing exemption for imported general cosmetics under a key implementing regulation drafted for China’s new cosmetics oversight framework.

Waiting For Cannabidiol Guidance? US FDA Reminds Industry Of ‘Many Other Requirements’

Two months after submitting CBD enforcement draft guidance for OMB review, FDA published separate draft guidance on studies for bioequivalents of an approved cannabidiol-based drug. But the draft guidance that the supplement industry awaits in pitched anticipation remains under review.

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel